Michael Ahearn, MD
Family Medicine · Kewanee, ILNPI 1184687717
Payments from drug & device makers
Across 85 payments — averaging $13.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$169
- Neurocrine Biosciences, Inc.$142
- Abbott$114
- AbbVie$75
- Pfizer$63
- Amarin Pharma, Inc.$46
- plus $519 from 20 others
What the payments were for
- Food & beverage$1,09597%
- Education$323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $169 |
| Neurocrine Biosciences, Inc. | 11 | $142 |
| Abbott | 6 | $114 |
| AbbVie(2 entities) | 4 | $75 |
| Pfizer | 4 | $63 |
| Amarin Pharma, Inc. | 3 | $46 |
| Eisai Inc. | 3 | $45 |
| Astellas Pharma US Inc | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Lilly USA, LLC | 3 | $37 |
| AstraZeneca | 3 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Dexcom, Inc. | 1 | $31 |
| Johnson & Johnson | 2 | $30 |
| Novartis | 2 | $30 |
| GSK | 2 | $27 |
| Exact Sciences | 1 | $26 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $17 |
| CMP Pharma, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Circassia Inc. | 1 | $11 |
How this compares
$1,127 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 271 | $1,250,919 |
| EliquisApixaban | 3,535 | $1,052,053 |
| JardianceEmpagliflozin | 2,063 | $639,470 |
| TrulicityDulaglutide | 654 | $468,777 |
| EntrestoSacubitril/Valsartan | 1,344 | $464,777 |
| FarxigaDapagliflozin Propanediol | 1,453 | $450,883 |
| Invega SustennaPaliperidone Palmitate | 140 | $408,793 |
| OzempicSemaglutide | 255 | $274,330 |
| XareltoRivaroxaban | 586 | $186,702 |
| AustedoDeutetrabenazine | 43 | $172,693 |
| MyrbetriqMirabegron | 810 | $171,774 |
| JanuviaSitagliptin Phosphate | 472 | $139,587 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 191 | $139,250 |
| LinzessLinaclotide | 237 | $139,229 |
| Tetrabenazine | 21 | $116,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $142 | $1,250,919271 claims |
| PfizerEliquis | $63 | $1,052,0533,535 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta | $30 | $640,495786 claims |
| Lilly USA, LLCTrulicity | $37 | $468,777654 claims |
| NovartisEntresto | $30 | $464,7771,344 claims |
| AstraZenecaFarxiga | $37 | $450,8831,453 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $27 | $301,254595 claims |
| Novo NordiskOzempic | $169 | $274,330255 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $42 | $172,69343 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $171,774810 claims |
| AbbVieLinzess | $75 | $139,229237 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $24 | $87,419121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Kewanee
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.